Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia

References

• Magliano DJ , Shaw JE , Shortreed SM , et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia . 2008;51(12):2179–2186. doi:10.1007/s00125-008-1150-5 18810385
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global Report On Diabetes . Published 4 2016 .
   Google Scholar
• Schofield D , Cunich MM , Shrestha RN , et al. The economic impact of diabetes through lost labour force participation on individuals and government: evidence from a microsimulation model. BMC Public Health . 2014;14:220. doi:10.1186/1471-2458-14-220 24592931
   PubMed Web of Science ®Google Scholar
• Wallick CJ , Hansen RN , Campbell J , Kiss S , Kowalski JW , Sullivan SD . Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina . 2015;46(7):744–751. doi:10.3928/23258160-20150730-09 26247456
   PubMed Web of Science ®Google Scholar
• Farrell C , Moran J . Comparison of comorbidities in patients with pre-diabetes to those with diabetes mellitus type 2. Ir Med J . 2014;107(3):72–74.24757888
   PubMedGoogle Scholar
• Liew G , Michaelides M , Bunce C . A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999-2000 with 2009–2010. BMJ Open . 2014;4(2):e004015. doi:10.1136/bmjopen-2013-004015
   PubMed Web of Science ®Google Scholar
• Bahrami B , Zhu M , Hong T , Chang A . Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia . 2016;59(8):1594–1608. doi:10.1007/s00125-016-3974-8 27179659
   PubMed Web of Science ®Google Scholar
• Bahrami B , Hong T , Gilles MC , Chang A . Anti-VEGF therapy for diabetic eye diseases. Asia Pac J Ophthalmol (Phila) . 2017;6(6):535–545. doi:10.22608/APO.2017350 29076303
   PubMed Web of Science ®Google Scholar
• Lally DR , Shah CP , Heier JS . Vascular endothelial growth factor and diabetic macular edema. Surv Ophthalmol . 2016;61(6):759–768. doi:10.1016/j.survophthal.2016.03.010 27045225
   PubMed Web of Science ®Google Scholar
• Lim LT , Chia SN , Ah-Kee EY , Chew N , Gupta M . Advances in the management of diabetic macular oedema based on evidence from the diabetic retinopathy clinical research network. Singapore Med J . 2015;56(5):237–247. doi:10.11622/smedj.2015071 26034315
   PubMed Web of Science ®Google Scholar
• Wells JA , Glassman AR , Ayala AR , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology . 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022 26935357
   PubMed Web of Science ®Google Scholar
• Aroney C , Fraser-Bell S , Lamoureux EL , Gillies MC , Lim LL , Fenwick EK . Vision-related quality of life outcomes in the BEVORDEX study: a clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci . 2016;57(13):5541–5546. doi:10.1167/iovs.16-19729 27768792
   PubMed Web of Science ®Google Scholar
• Boyer DS , Yoon YH , Belfort R Jr. , et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology . 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024 24907062
   PubMed Web of Science ®Google Scholar
• Hussain RM , Ciulla TA . Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther . 2016;16(3):365–374. doi:10.1517/14712598.2016.1131265 26674182
   PubMed Web of Science ®Google Scholar
• Pacella F , Romano MR , Turchetti P , et al. An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol . 2016;9(10):1427–1432. doi:10.18240/ijo.2016.10.10 27803859
   PubMed Web of Science ®Google Scholar
• Pershing S , Enns EA , Matesic B , Owens DK , Goldhaber-Fiebert JD . Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med . 2014;160(1):18–29. doi:10.7326/M13-0768 24573663
   PubMed Web of Science ®Google Scholar
• Abraham NG , Srinivasan K , Thomas J . Normative data for near point of convergence, accommodation, and phoria. Oman J Ophthalmol . 2015;8(1):14–18. doi:10.4103/0974-620X.149856 25709268
   PubMedGoogle Scholar
• Bucolo C , Gozzo L , Longo L , Mansueto S , Vitale DC , Drago F . Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies. J Pharmacol Sci . 2018;138(4):219–232. doi:10.1016/j.jphs.2018.11.001 30503676
   PubMed Web of Science ®Google Scholar
• Couturier A , Rey PA , Erginay A , et al. Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology . 2019. doi:10.1016/j.ophtha.2019.06.022.
   Web of Science ®Google Scholar
• Williams R , Airey M , Baxter H , Forrester J , Kennedy-Martin T , Girach A . Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) . 2004;18(10):963–983. doi:10.1038/sj.eye.6701476 15232600
   PubMed Web of Science ®Google Scholar
• Tapp RJ , Shaw JE , Harper CA , et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care . 2003;26(6):1731–1737. doi:10.2337/diacare.26.6.1731 12766102
   PubMed Web of Science ®Google Scholar
• Gonder JR , Walker VM , Barbeau M , et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol . 2014;2014:939315. doi:10.1155/2014/939315 24795818
   PubMed Web of Science ®Google Scholar
• Spooner KL , Mhlanga CT , Hong TH , Broadhead GK , Chang AA . The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol . 2018;12:2483–2491. doi:10.2147/OPTH.S185052 30584267
   PubMed Web of Science ®Google Scholar
• Vaze A , Fraser-Bell S , Gillies M . Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta Ophthalmol (Copenh) . 2014;92(8):e697–e698. doi:10.1111/aos.12417
   Web of Science ®Google Scholar
• Polonsky WH , Henry RR . Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence . 2016;10:1299–1307. doi:10.2147/PPA.S106821 27524885
   PubMed Web of Science ®Google Scholar
• Suner IJ , Bressler NM , Varma R , Dolan CM , Ward J , Turpcu A . RESPONSIVENESS OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE-25 TO VISUAL ACUITY GAINS IN PATIENTS WITH DIABETIC MACULAR EDEMA: evidence from the RIDE and RISE trials. Retina (Philadelphia, Pa) . 2017;37(6):1126–1133. doi:10.1097/IAE.0000000000001316
   Web of Science ®Google Scholar
• Hanemoto T , Hikichi Y , Kikuchi N , Kozawa T . The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS One . 2017;12(12):e0189035. doi:10.1371/journal.pone.0189035 29220371
   PubMed Web of Science ®Google Scholar
• Lee CM , Colagiuri R , Magliano DJ , et al. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract . 2013;99(3):385–390. doi:10.1016/j.diabres.2012.12.002 23298663
   PubMed Web of Science ®Google Scholar
• Megari K . Quality of life in chronic disease patients. Health Psychol Res . 2013;1(3):e27. doi:10.4081/hpr.2013.932 26973912
   PubMedGoogle Scholar
• Granstrom T , Forsman H , Leksell J , Jani S , Raghib AM , Granstam E . Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema. J Diabetes Complications . 2015;29(8):1183–1190. doi:10.1016/j.jdiacomp.2015.07.026 26318959
   PubMed Web of Science ®Google Scholar
• Okamoto Y , Okamoto F , Hiraoka T , Oshika T . Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy. Jpn J Ophthalmol . 2014;58(4):369–374. doi:10.1007/s10384-014-0323-7 24777841
   PubMed Web of Science ®Google Scholar
• Turkoglu EB , Celik E , Aksoy N , Bursali O , Ucak T , Alagoz G . Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment? J Diabetes Complications . 2015;29(4):540–543. doi:10.1016/j.jdiacomp.2015.03.009 25817172
   PubMed Web of Science ®Google Scholar
• Fritschi C , Quinn L . Fatigue in patients with diabetes: a review. J Psychosom Res . 2010;69(1):33–41. doi:10.1016/j.jpsychores.2010.01.021 20630261
   PubMed Web of Science ®Google Scholar
• Polat O , Inan S , Ozcan S , et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol . 2017;47(4):205–210. doi:10.4274/tjo.28003 28845324
   PubMedGoogle Scholar
• Stewart MW . Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med . 2015;4(5):1079–1101. doi:10.3390/jcm4051079 26239466
   PubMed Web of Science ®Google Scholar
• Gupta OP , Shienbaum G , Patel AH , Fecarotta C , Kaiser RS , Regillo CD . A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology . 2010;117(11):2134–2140. doi:10.1016/j.ophtha.2010.02.032 20591490
   PubMed Web of Science ®Google Scholar